These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27853651)

  • 1. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.
    Magee MS; Kraft CL; Abraham TS; Baybutt TR; Marszalowicz GP; Li P; Waldman SA; Snook AE
    Oncoimmunology; 2016; 5(10):e1227897. PubMed ID: 27853651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
    Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
    Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
    Snook AE; Baybutt TR; Hyslop T; Waldman SA
    Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
    Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GUCY2C-targeted cancer immunotherapy: past, present and future.
    Snook AE; Magee MS; Waldman SA
    Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
    Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
    J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
    Marszalowicz GP; Snook AE; Magee MS; Merlino D; Berman-Booty LD; Waldman SA
    Oncotarget; 2014 Oct; 5(19):9460-71. PubMed ID: 25294806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
    Rappaport JA; Waldman SA
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
    [No Abstract]   [Full Text] [Related]  

  • 10. TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.
    Abraham TS; Flickinger JC; Waldman SA; Snook AE
    J Immunol; 2019 Feb; 202(4):1301-1310. PubMed ID: 30642983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.
    Flickinger JC; Singh J; Yarman Y; Carlson RD; Barton JR; Waldman SA; Snook AE
    Front Immunol; 2022; 13():855759. PubMed ID: 35355987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
    Flickinger JC; Singh J; Carlson R; Leong E; Baybutt TR; Barton J; Caparosa E; Pattison A; Rappaport JA; Roh J; Zhan T; Bashir B; Waldman SA; Snook AE
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
    Snook AE; Li P; Stafford BJ; Faul EJ; Huang L; Birbe RC; Bombonati A; Schulz S; Schnell MJ; Eisenlohr LC; Waldman SA
    Cancer Res; 2009 Apr; 69(8):3537-44. PubMed ID: 19351847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.
    Lisby AN; Flickinger JC; Bashir B; Weindorfer M; Shelukar S; Crutcher M; Snook AE; Waldman SA
    Expert Rev Precis Med Drug Dev; 2021; 6(2):117-129. PubMed ID: 34027103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.
    Song DG; Ye Q; Poussin M; Liu L; Figini M; Powell DJ
    Oncotarget; 2015 Aug; 6(25):21533-46. PubMed ID: 26101914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia.
    Rappaport JA; Waldman SA
    Front Oncol; 2018; 8():299. PubMed ID: 30131940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.
    Bashir B; Merlino DJ; Rappaport JA; Gnass E; Palazzo JP; Feng Y; Fearon ER; Snook AE; Waldman SA
    Hum Pathol; 2019 May; 87():103-114. PubMed ID: 30716341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
    Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
    Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
    Entezari AA; Snook AE; Waldman SA
    Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.